Media

• 8
  GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024
  10-29
• 7
  GemVax's GV1001 Reduces Alzheimer’s Amyloid Beta to Normal Levels
  09-30
• 6
  GemVax & KAEL Co., Ltd. Confirms Participation as Signature Sponsor at Neuro2024
  09-25
• 5
  GemVax Confirms Potential for Preventing Alzheimer's Disease in Periodontitis Patients with GV1001
  06-05
• 4
  GemVax Completes Global Phase 2 Patient Recruitment for Alzheimer’s Disease Drug
  04-12
• 3
  GemVax Completes Phase 2 Patient Recruitment for Progressive Supranuclear Palsy Trial
  03-28
• 2
  GV1001, GemVax's Progressive Supranuclear Palsy Treatment, Designated as Orphan Drug by Ministry of Food and Drug Safety
  02-23
• 1
  GemVax Receives FDA Phase 2 IND Approval for 'GV1001' in the Treatment of Progressive Supranuclear Palsy
  02-13

게시물 검색

Subject Content Subject+Content User ID User ID(코) Writer Writer(코)